Trial reportEuropean journal of clinical pharmacology2021
Sertraline concentrations in pregnant women are steady and the drug transfer to their infants is low.
Trial report in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects and Consequences for Mother and Child From Treatment for Depression, A Prospective Randomized, Placebo- Controlled, Trial With Internet-based Cognitive Behavior Therapy and Sertraline or Placebo for Moderate Depression in Pregnancy
The Effectiveness of Psychopharmacological Intervention Versus Cognitive Behavioral Couple Therapy and Their Combination in Perinatal Distressed Couples: A Randomized Clinical Trial
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Benefits and Risks of Antidepressant Drugs During Pregnancy: A Systematic Review of Meta-analyses.Paediatric drugs · 2023Pooled it
- Variability in Sertraline Pharmacokinetics in Routine Clinical Practice: Influence of Sex, Age, Body Weight, Smoking, and Co-Medication.Fundamental & clinical pharmacology · 2026Observational
- Prenatal serotonin reuptake inhibitor exposure and maternal depression symptoms are associated with altered fetal brain and placental development.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Observational
- Folic acid attenuates maternal sertraline-induced hepatic injury in rat offspring.Scientific reports · 2026Article
- Effect of Sertraline on Fetoplacental Growth Parameters and Placental Transporter Gene Expression in Rats.International journal of molecular sciences · 2026Article
- Pharmacokinetic profiles of sertraline in pregnancy as a predictor of postpartum depressive symptoms.British journal of clinical pharmacology · 2026Observational
- Prediction of Maternal and Fetal Exposure to Escitalopram, Sertraline, and Paroxetine by Combining Human Ex Vivo Placenta Perfusion Data and Physiologically Based Pharmacokinetic Modeling.Clinical pharmacokinetics · 2025Article
- Zinc Phosphide Poisoning in Pregnancy: A Rare Case Report From Nepal.Clinical case reports · 2025Article
- Peripartum sertraline impacts maternal neurobehavioral and neurodegenerative mechanisms in pregnant and postpartum mice.Molecular psychiatry · 2025Article
- Effects of selective serotonin reuptake inhibitors on the placenta†.Biology of reproduction · 2025Review
- The sertraline metabolite, desmethylsertraline, may be implicated in adverse outcomes reported after gestational sertraline use: insights from a study in zebrafish.Pharmacological reports : PR · 2025Article
- Sertraline use in pregnancy and placental transfer: A pharmacokinetic prospective cohort study.Pregnancy (Hoboken, N.J.) · 2025Article
- Folic Acid Mitigates Sertraline-Induced Liver Damage in Adult Female Albino Rats During Pregnancy and Postpartum: A Biochemical and Histological Study.Medicina (Kaunas, Lithuania) · 2025Article
- Investigating Remedial Strategies for Missed or Delayed Dose of Sertraline in Chinese Adolescent Patients with Depressive Disorders via Population Pharmacokinetics Modeling and Simulation Approaches.Drug design, development and therapy · 2025Article
- Supplementary approaches to perinatal depression: a review of pathogenesis, herbal interventions, and dietary supplements.Frontiers in psychology · 2025Review
- Sertraline-induced 5-HT dysregulation in mouse cardiomyocytes and the impact on calcium handling.American journal of physiology. Heart and circulatory physiology · 2024Article
- Brain structural and functional outcomes in the offspring of women experiencing psychological distress during pregnancy.Molecular psychiatry · 2024Review
- Population pharmacokinetic approach to guide personalized sertraline treatment in Chinese patients.Heliyon · 2024Article
- Switching pattern and dose adjustment of antidepressants before and during pregnancy.Archives of women's mental health · 2023Article
- Pharmacokinetics of Antidepressants in Pregnancy.Journal of clinical pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
purposeSertraline, a selective serotonin reuptake inhibitor (SSRI), is one of the most commonly used antidepressant during pregnancy. Plasma sertraline concentrations vary markedly between individuals, partly explained by variability in hepatic drug metabolizing cytochrome P450-enzyme activity. Our purpose was to study the variability in the plasma concentrations in pregnant women and the passage to their infants.
methodPregnant women with moderate untreated depression were recruited in 2016-2019 in Stockholm Region and randomized to treatment with sertraline or placebo. All received Internet-based cognitive behavior therapy as non-medical treatment. Sertraline plasma concentrations were measured around pregnancy weeks 21 and 30, at delivery, 1-month postpartum, in cord blood and at 48 h of age in the infant. The clinical course of the infants was followed.
resultsNine mothers and 7 infants were included in the analysis. Median dose-adjusted sertraline concentration in second trimester was 0.15(ng/mL) /(mg/day), in third trimester and at delivery 0.19 and 1-month postpartum 0.25, with a 67% relative difference between second trimester and postpartum. The interindividual variation was 10-fold. Median concentrations in the infants were 33% and 25% of their mothers', measured in cord blood, and infant plasma, respectively. Only mild and transient adverse effects were seen on the infants.
conclusionPlacental passage of sertraline to the infant is low. However, the interindividual variation in maternal concentrations during pregnancy is huge, why therapeutic drug monitoring might assist in finding the poor metabolizers at risk for adversity and increase the safety of the treatment.
trial registrationThe trial was registered at clinicaltrials.gov July 9, 2014 with TRN: NCT02185547.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.